Dr. Roboz on the QuANTUM-R Trial in AML
Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.
Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus salvage chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.
Patients who have relapsed or refractory FLT3-mutated AML have a poor prognosis, a high frequency of relapse, and poor response to salvage therapy.
This patient population has a high unmet need for appropriate therapy, and quizartinib, a second-generation FLT3 inhibitor, was investigated as a proposed treatment in the QuANTUM-R study, which is a randomized, controlled, phase III trial at 152 centers that compared the proposed agent with chemotherapy in patients with FLT3-mutated AML.
Roboz explains that the completed phase III study showed that treatment with quizartinib had a survival benefit versus salvage chemotherapy. Moreover, the agent also demonstrated an acceptable safety profile.
